Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. (PHAT) priced its initial public offering on Oct 28, 2019 at $19.00 per share, raising $181.7M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $523.4M. Goldman Sachs was lead-left underwriter, joined by Jefferies, Evercore ISI and Needham. Latham & Watkins advised the company and Cooley advised the underwriters.

Phathom Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company developing treatments for gastrointestinal diseases. Its initial candidate, vonoprazan, is an oral potassium competitive acid blocker studied for gastroesophageal reflux disease and, with antibiotics, for H. pylori infection, and is approved in several Asian and Latin American countries.

Status

IPO

Ticker

PHAT

Exchange

Nasdaq Global Select

Priced

Oct 28, 2019

IPO price

$19.00

Raised

$181.7M

Market cap at IPO price

$523.4M

First filed

Sep 30, 2019

Underwriters

Goldman Sachs, Jefferies, Evercore ISI and Needham

Company counsel

Latham & Watkins

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

NJ

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.